Pfizer Inc. (NYSE:PFE - Get Free Report) fell 0.5% during trading on Wednesday . The company traded as low as $26.04 and last traded at $26.18. 6,291,521 shares traded hands during trading, a decline of 85% from the average session volume of 41,648,453 shares. The stock had previously closed at $26.32.
Analyst Upgrades and Downgrades
PFE has been the topic of several research analyst reports. Argus cut shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They set a "buy" rating and a $36.00 price objective for the company. TD Cowen lowered Pfizer from an "outperform" rating to a "market perform" rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has an average rating of "Hold" and a consensus price target of $36.33.
Get Our Latest Stock Report on PFE
Pfizer Trading Down 0.2 %
The firm has a market capitalization of $148.70 billion, a price-to-earnings ratio of 72.94, a PEG ratio of 1.18 and a beta of 0.61. The business's 50-day moving average price is $27.05 and its 200 day moving average price is $28.50. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69.
Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.29. The firm had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm's revenue was down 41.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.14 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.24 earnings per share for the current fiscal year.
Pfizer Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.40%. Pfizer's dividend payout ratio (DPR) is 466.67%.
Institutional Investors Weigh In On Pfizer
Hedge funds and other institutional investors have recently modified their holdings of the stock. Briaud Financial Planning Inc bought a new position in Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. acquired a new position in Pfizer in the third quarter worth $34,000. VisionPoint Advisory Group LLC increased its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. GoalVest Advisory LLC raised its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 811 shares during the period. Finally, Creekmur Asset Management LLC bought a new position in shares of Pfizer in the 4th quarter worth about $32,000. Institutional investors own 68.36% of the company's stock.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
